The acute inotropic effects of cardiac contractility modulation (CCM) are associated with action potential duration shortening and mediated by β1-adrenoceptor signalling

James Winter a, Kieran E. Brack a, G. André Ng a,b,*

a Cardiology group, Department of Cardiovascular Sciences, University of Leicester, LE3 9QP, UK
b Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK

Abstract

Despite promising results in clinical trials conducted to date, little is known about how cardiac contractility modulation (CCM) mediated inotropic enhancement occurs and how CCM affects the electrophysiological characteristics of the heart. The aims of the present study were to 1) investigate how the stimulation parameters of the CCM signal and the location of stimulus delivery influence the contractile response, 2) characterise the effect of CCM on ventricular electrophysiology, and 3) investigate the potential physiological mechanisms underlying these acute inotropic and electrophysiological effects. Experiments were conducted in isolated rabbit hearts with simultaneous measurement of ventricular contractility and monophasic action potential duration (MAPD). Biphasic square wave pulses were applied to the left ventricle, timed to coincide with the absolute refractory period. CCM mediated responses were assessed over a range of signal amplitudes (2–30 mA), durations (2–15 ms) and delays from the activation of the locally recorded monophasic action potential (0–30 ms). Responses were assessed during perfusion with the β1-adrenoceptor antagonist metoprolol (1.8 μM) and HMR 1556 (500 nM), an inhibitor of the slow delayed rectifying potassium current. Norepinephrine content was collected and assessed by ELISA from samples of coronary effluent collected during CCM. CCM induced a significant increase in left ventricular pressure (LVP) in a manner dependent upon the amplitude and duration of the CCM signal but independent of the delay of the stimulus within the action potential plateau and was associated with an increase in norepinephrine in coronary effluent (Mean: 46 ± 9 pg/ml). CCM promoted a shortening of MAPD-90% close to the site of stimulation (∼19 ± 3%) but had no effect on those recorded at distant sites (0 ± 1%). The increase in LVP (4.7 ± 1.8 vs. 0.7 ± 0.9%, P<0.01) and shortening of local MAPD-90% (∼15 ± 3 vs. 1 ± 1%, P<0.01) was abolished with metoprolol. Perfusion with HMR 1556 caused a significant inhibition of local MAPD shortening (∼27 ± 2 vs. −21 ± 3 ms, P<0.05). CCM is associated with a shortening of ventricular MAPD in a manner dependent upon β1-adrenoceptor stimulation resulting from catecholamine release, a finding which may be of clinical significance in regard to the development of malignant ventricular arrhythmias. This article is part of a Special Issue entitled Possible Editorial.

© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.

Keywords:
Cardiac contractility modulation
Non-excitatory stimulation
Rabbit
Sympathetic nerves
Langendorff

1. Introduction

Application of electrical currents to the myocardium during the absolute refractory period of the ventricular action potential enhances ventricular inotropy in vivo and in a wide range of isolated cardiac tissue preparations [1–4]. This effect, termed cardiac contractility modulation (CCM) is a novel therapeutic treatment for use in patients with heart failure who are unresponsive to conventional drug therapies and/or ineligible for/unresponsive to cardiac resynchronisation therapy. Despite several studies on CCM, little is known about the mechanisms by which this form of non-excitatory stimulation enhances ventricular contractility.

It is possible that electrical stimulation of the myocardium could stimulate autonomic nerves within the myocardium and thereby promote the release of adrenergic neurotransmitters from sympathetic nerve terminals. However, experimental evidence to date has been conflicting. Early reports in isolated rabbit papillary muscles demonstrated that inotropic response to CCM was unchanged during pharmacological β1-adrenoceptor blockade [4]. Similarly the inotropic effects of CCM were not blocked in isolated ferret hearts perfused with the β-adrenoceptor antagonist propranolol [3], although there was a trend for towards a reduction in left ventricular inotropy and systolic level of the Ca2+ transient. More recently, Meyer et al. reported that
application of electrical signals within the coronary sinus during the absolute refractory period (similar to CCM) in sheep promoted an increase in ventricular pressure development that was abolished when these animals were pre-treated with propranolol [5], providing indirect evidence that application of electrical signals to the heart during the refractory period could stimulate the release of sympathetic neurotransmitters.

In addition to an increase in contractility, early studies in isolated papillary muscles [4] suggested that CCM prolongs action potential duration and indicated a potential direct effect of CCM on sarcomemmal ion channels (e.g. the L-type Ca\(^{2+}\) channel). To our knowledge these findings have yet to be confirmed in the whole heart. As the activation and recovery of specific depolarising and repolarising currents change over the cardiac cycle, it is important to assess whether differences in the parameters of the CCM signal would influence the inotropic and electrophysiological response to CCM. This is supported by the lack of such data within the literature. In addition, knowledge of the effect of CCM signal parameters on the response may be of clinical importance to establish clinical efficacy. The role of adrenergic neurotransmitter release and concurrent β-adrenoceptor activation in the acute mechanisms of CCM induced inotropy require further investigation as do the electrophysiological effects of CCM in the whole heart.

The aims of the present study are to 1) investigate how the stimulation parameters of the CCM signal and the location of stimulus delivery influence the contractile response in, 2) characterise the effect of CCM on ventricular electrophysiology, and 3) investigate the potential physiological mechanisms underlying these acute inotropic and electrophysiological effects in isolated rabbit hearts.

2. Materials and methods

2.1. Animal welfare

All procedures were undertaken in accordance with ethical guidelines set out by the UK Animals (Scientific Procedures) Act 1986 and conformed to the Guide for the Care and Use of Laboratory Animals Published by the US National Institutes of Health (NIH Publication No.85−23, revised 1985).

2.2. Langendorff tissue isolation and perfusion

Adult male New Zealand White rabbits (2.0–2.5 kg, n = 21) were pre-medicated with ketamine (Ketaset, 10 mg/kg, Fort Dodge, Southampton, UK), medetomidine hydrochloride (Sedator, 0.2 mg/kg, Dechra, Shrewsbury, UK) and butorphanol (Torbugesic, 0.05 mg/kg, Fort Dodge Southhampton, UK) (i.m.). 15–20 min later, animals were sacrificed with an overdose of pentobarbitone sodium (Sagatal, Rhone Merieux, Harlow, UK; 0.8 mg/kg, body weight, i.v.) containing Heparin (1000 IU, Multiparin, Wrexham, United Kingdom) via the marginal ear vein. The hearts were rapidly excised and retrogradely perfused through the ascending aorta (40 ml/min) using a Gilson Minipulse 3 peristaltic pump (Anachem, Luton, UK). The heart was perfused with Tyrode solution of the following composition (mM): Na\(^+\) 138.0, K\(^+\) 4.0, Ca\(^{2+}\) 1.8, Mg\(^2+\) 1.0, HCO\(_3\)\(^−\) 24.0, H\(_2\)PO\(_4\) 0.4, Cl\(^−\) 121.0, glucose 11.0 and acetate 20.0. The solution was continuously bubbled with 95% O\(_2\)−5% CO\(_2\) to maintain a constant pH of 7.4. Temperature was maintained at 37 °C. A 3F polypropylene catheter (Portex, Kent, United Kingdom) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intra-ventricular left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intra-ventricular left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intra-ventricular left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intra-ventricular left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricle (LV) for drainage of Thebesian venous effluent. Intravenous left ventricular pressure (LVP) was inserted at the apex of the left ventricular signal. A square wave bipolar signal is applied directly to the surface of the LV during the absolute refractory period. Signal delay is timed from the point of activation of a locally recorded monophasic action potential.
2.5.2. Stimulus parameters

In this protocol CCM signals were delivered solely to basal regions (electrode spacing: 5 mm). All 3 following parameters were examined in the same hearts (n = 6).

2.5.2.1. Stimulus amplitude. Signal duration = 10 ms per phase, Signal delay = + 10 ms, Signal amplitude was varied between 4 and 30 mA during sequential stimulations.

2.5.2.2. Stimulus duration. Signal amplitude = 20 mA, Signal delay = + 10 ms. Signal duration was varied between 4 and 30 ms (2 and 15 ms per phase respectively).

2.5.2.3. Stimulus delay. Signal amplitude = 20 mA, signal duration = 10 ms per phase. Signal delay was timed to coincide with the activation of locally recorded MAPs (delay of 0 ms = time of activation). Signal delay was increased in 10 ms steps, in sequential stimulations, from 0 to 40 ms.

2.5.3. Mechanisms of CCM

Signal amplitude = 20 mA, signal duration = 10 ms per phase, Signal delay = + 10 ms. The CCM response was optimised from data obtained from the experiments described above.

2.5.3.1. Role of β-adrenoceptor activation. Responses were compared before and during perfusion with the β1-adrenoceptor antagonist metoprolol (1.8 μM, Sigma-Aldrich, Gillingham, UK).

2.5.3.2. Release of noradrenaline. Samples of coronary effluent (1 ml) were collected before, during and after CCM at both low (5 mA) and high (20 mA) amplitudes of CCM stimulation. Noradrenaline content in these samples was measured directly using a competitive enzyme linked immunosorbance assay (ELISA) (BA E-5200, Griffin Life Sciences, Abingdon, UK).

2.5.3.3. Mechanism of CCM activated MAPD shortening. The slow delayed rectifier potassium current is known to be involved in β-adrenoceptor induced shortening of action potential duration [6–10]. In the current study, alterations in monophasic action potential duration (MAPD) were examined during perfusion with a specific inhibitor of Ikss, [(3R,4S)-(+)-N-[3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy) chroman-4-yl]-N-methylmethanesulfonamide (HMR1556 500nM, Sanofi-Aventis, Frankfurt, Germany). The efficacy of HMR 1556 was confirmed during perfusion with the non-selective β-adrenoceptor agonist isoprenaline (ISO), at a dose (5 nM) that produces a similar degree of inotropy and MAPD shortening to that noted during CCM. Responses to ISO and CCM (signal amplitude = 20 mA, signal duration = 10 ms per phase, Signal delay = + 10 ms) were compared before and after perfusion of HMR 1556. All hearts were paced at a rate of 250 bpm to circumvent the chronotropic effects of ISO on the sino-atrial node.

2.6. Signal measurements and analysis

All signals were recorded with a PowerLab 8s system and digitised at 2 kHz using Chart and Scope software (ADInstruments Ltd). Left ventricular contractile performance was assessed from an average of 20 beats during baseline and during the steady response plateau. MAPD was measured at 90% repolarisation (MAPD90) averaged over 20 beats recorded during steady state before and immediately after the cessation of CCM stimulation. This was necessary due to signal interference from the CCM signal preventing measurement of MAPs during CCM signal application. MAPD90 calculations were performed using custom written analysis software (NewMap, Dr. F. Burton, University of Glasgow, UK).

2.7. Statistics

Statistical comparisons were made using Student paired t tests, one or two way ANOVA where appropriate with Bonferroni post hoc test. All data are presented as mean values ± SEM. P < 0.05 was considered significant.

3. Results

3.1. Inotropic and electrophysiological response to CCM

Fig. 2 illustrates the effect of CCM on perfusion pressure, left ventricular pressure, rate of pressure production and relaxation, and left ventricular epicardial monophasic action potentials in a typical experiment. Localised application of electrical signals to the epicardium

![Fig. 2. Effect of CCM signal delivery on left ventricular contractility and electrophysiology. Left panel. Raw data illustrating the effect of CCM on perfusion pressure (AP), left ventricular pressure (LVP) and peak LVP. Right panel. Averaged LVP profiles taken from Left panel, illustrating the rate of pressure development and relaxation together with the corresponding monophasic action potentials at baseline (black) and during steady state CCM (red). Stimulation parameters: Duration = 10 ms, Delay = 10 ms, Amplitude = 20 mA, (n = 1).]
of the LV promoted an increase in global pressure development (peak LVP) and rates of pressure development (dP/dt\text{max}). The increase in peak LVP occurred within 2 to 5 s after application of the CCM signal and increased to an initial peak before decreasing to a new steady state that was higher than baseline. Following cessation of CCM, peak LVP gradually returned to baseline values within 2 to 3 min. There was no significant effect from CCM on the rate of ventricular relaxation (dP/dt\text{min, baseline} = −976 ± 95 mm Hg/s) or on perfusion pressure (AP, baseline = 63 ± 5 mm Hg). Left ventricular end diastolic pressure was similarly unaffected during CCM (baseline = 5 ± 1 mm Hg). CCM resulted in a shortening of monophasic action potential, compared immediately before and immediately after CCM, which recovered to baseline values 2–3 min following the cessation of stimulation.

3.2. Effect of stimulus location on the response to CCM

Mean data illustrating the percentage change in peak LVP, dP/dt\text{max} and MAPD\text{90}, recorded from multiple sites simultaneously, are shown in Fig. 3. CCM signals applied to basal (75 ± 6 vs. 78 ± 6 mm Hg, P < 0.01) and midlevel (74 ± 5 vs. 77 ± 5 mm Hg, P < 0.01) regions promoted significant increases in peak LVP. dP/dt\text{max} was similarly significantly enhanced during CCM stimulation at basal (1205 ± 129 vs. 1355 ± 148 mm Hg/s, P < 0.01) and midlevel (1200 ± 104 vs. 1351 ± 126 mm Hg/s, P < 0.01) regions. CCM in apical regions was not associated with any significant change in ventricular inotropy. MAPD\text{90} shortening was evident at regions close to the site of stimulation. During application of CCM at basal regions there was significant −21 ± 4 ms (108 ± 6 vs. 88 ± 7 ms, P < 0.01) decrease in locally recorded MAPD\text{90} and no change demonstrated in distant MAPD\text{90} recorded from the left ventricular apex (106 ± 6 vs. 106 ± 6 ms). Stimulation in apical regions resulted in a significant −16 ± 5 ms (110 ± 4 vs. 91 ± 4 ms, P < 0.05) reduction in locally recorded MAPD\text{90} and no significant change in basal MAPD\text{90} (110 ± 4 vs. 111 ± 3 ms). Midlevel stimulation promoted a significant reduction in basal (−12 ± 5 ms) but not apical MAPD\text{90}. There was no difference in the degree of shortening of locally recorded MAPD\text{90} between apical and basal stimulations (−21 ± 4 vs. −16 ± 5 ms, P = NS).

3.3. Effect of varying the stimulus parameters on the response to CCM

3.3.1. Amplitude

The effect of CCM signal amplitude on peak LVP, dP/dt\text{max} and MAPD\text{90} from 6 hearts is shown in Fig. 4. Significant increases in peak LVP were noted at stimulus amplitudes of 15 (3.4±0.9 mm Hg, P < 0.01), 20 (3.9±1.2 mm Hg, P < 0.001) and 30 mA (3.7±0.9 mm Hg, P < 0.001). Similarly dP/dt\text{max} was enhanced at stimulus amplitudes of 15 mA or greater. The percentage change in peak LVP and dP/dt\text{max} was related to the stimulus amplitude in a monotonic manner, increasing to a plateau at stimulus amplitudes >15 mA.

Fig. 3. Heterogeneity of CCM response across the heart. Data illustrating the percentage change in peak left ventricular pressure (LVP, Panel A), maximal rate of change of pressure increase (dP/dt\text{max}, Panel B) and apical and basal monophasic action potential duration (MAPD\text{90}, Panel C) during CCM at different epicardial sites. Sites of stimulation; A=Apex, M=Midlevel, B=Base. (n=6) Heterogeneity of response to regional stimulation: *P < 0.05, **P < 0.01, ***P < 0.001. Proximal vs. distal MAP (see text for discussion): #P < 0.05, ##P < 0.01.
As i g n i f i c a n t shortening of locally recorded MAPD₉₀ was noted at stimulus amplitudes of 15 (28±7 ms, \( P < 0.01 \)), 20 (35±5 ms, \( P < 0.001 \)) and 30 mA (37±7 ms, \( P < 0.001 \)). A monotonic relationship was observed between the percentage change in MAPD₉₀ and the stimulus amplitude, demonstrating a plateau at stimulus amplitudes above 20 mA.

3.3.2. Duration

The effect of CCM signal duration on peak LVP, \( \frac{dP}{dt_{\text{max}}} \), and MAPD₉₀ from 6 hearts is shown in Fig. 5. A significant increase in peak LVP was noted at stimulus durations of 2 (2.0±0.4 mm Hg, \( P < 0.01 \)), 5 (2.5±0.4 mm Hg, \( P < 0.001 \)), 10 (3.5±0.6 mm Hg, \( P < 0.001 \)) and 15 ms (3.3±0.5 mm Hg, \( P < 0.001 \)). Similarly \( \frac{dP}{dt_{\text{max}}} \) was enhanced at all stimulus durations. The percentage change in peak LVP and \( \frac{dP}{dt_{\text{max}}} \) was related to the stimulus duration in a monotonic manner, increasing to a plateau at stimulus durations >10 ms.

A significant shortening of locally recorded MAPD₉₀ was noted at stimulus durations of 2 (18±4 ms, \( P < 0.01 \)), 5 (22±4 ms, \( P < 0.001 \)), 10 (29±6 ms, \( P < 0.001 \)) and 15 ms (26±6 ms, \( P < 0.001 \)). A monotonic relationship was observed between the percentage change in peak LVP and \( \frac{dP}{dt_{\text{max}}} \). 
in MAPD_{90} and stimulus amplitude, demonstrating a plateau at stimulus amplitudes > 10 ms.

3.3.3. Delay
The effect of time delay from MAP activation to CCM signal on peak LVP, dP/dt_{max} and MAPD_{90} from 6 hearts is shown in Table 1. A significant increase in peak LVP and dP/dt_{max} was noted at each delay investigated (0–30 ms). The increase in peak LVP (3.5 ± 0.5 mm Hg, P<0.05) and dP/dt_{max} (126 ± 14 mm Hg/s, P<0.05) during CCM was not significantly different at any delay studied. The shortening of MAPD_{90} was similarly unrelated to the timing of CCM signals during the absolute refractory period (-23 ± 3 ms, P<0.01).

3.4. Mechanisms of CCM induced inotropy and electrophysiological changes
3.4.1. Role of β-adrenoceptors
To investigate the role of β-adrenoceptor stimulation, we examined the effects of CCM in the absence and presence of the β₁-adrenoceptor antagonist metoprolol. Raw and mean data illustrating the effect of CCM

Fig. 5. Effect of varying signal duration on the ventricular responses to CCM. Data illustrating the effect of varying the duration of the CCM signal on peak left ventricular pressure (LVP, Panels A and B), rate of pressure development (dP/dt_{max}, Panels C & D) and mono-phasic action potential duration (MAPD_{90}, Panels E and F) (n = 6). CCM vs. Baseline; *P<0.05, **P<0.01, ***P<0.001.
on peak LVP and locally recorded MAPD$_{90}$ are presented in Fig. 6. Perfusion with metoprolol abolished the increase in peak LVP ($3.3 \pm 1$ vs. $0.3 \pm 0.4$ mm Hg, $P < 0.05$), $dP/dt_{\text{max}}$ (166 $\pm 30$ vs. 44 $\pm 4$ mm Hg/s, $P < 0.01$) and the shortening of locally recorded MAPD$_{90}$ induced by CCM ($-17 \pm 4$ vs. $0.2 \pm 1.24$ ms, $P < 0.05$).

### 3.4.2. Role of catecholamine release

To establish whether CCM stimulated noradrenaline release was an underlying mechanism of action for the effects observed, we measured noradrenaline content in samples of coronary effluent collected before, during and after CCM. Mean data from 4 hearts illustrating noradrenaline release and the change in peak LVP from baseline values at two stimulation amplitudes are illustrated in Fig. 7. CCM at both low (5 mA) and high (20 mA) amplitudes resulted in the detection of noradrenaline increase in the coronary effluent. Noradrenaline content returned to baseline values following the cessation of stimulation. Significantly more noradrenaline was measured during stimulation at high stimulus amplitude when compared to low stimulus amplitude ($46 \pm 9$ vs. $17 \pm 5$ pg/ml, $P < 0.05$). The mean steady state increase in peak LVP was greater during high than low stimulus amplitudes ($7.2 \pm 1.7$ vs. $2.9 \pm 0.7$ mm Hg, $P < 0.05$).

### 3.4.3. Mechanism of MAPD shortening

To investigate if MAPD shortening was mediated via the slow activating delayed rectifier channel $I_{Ks}$, the effects of CCM were studied during perfusion with HMR 1556 (500 nM), an inhibitor of $I_{Ks}$ and compared with the effects of perfusion with isoprenaline (ISO). Mean data from 6 hearts illustrating the effects of HMR 1556 on the shortening of MAPD$_{90}$ induced by CCM ($-27 \pm 3$ vs. $-11 \pm 1$ ms, $P < 0.001$). In the presence of HMR 1556, the effects of ISO on MAPD were reduced by $58 \pm 4\%$ ($-27 \pm 3$ vs. $-11 \pm 1$ ms, $P < 0.05$). The change in peak LVP associated with ISO was unaffected by HMR 1556. The shortening of MAPD$_{90}$ associated with CCM was reduced by $26 \pm 9\%$ ($-33 \pm 2$ vs. $-25 \pm 4$ ms, $P < 0.05$) in the presence of HMR 1556. HMR 1556 had no effect on the increase in peak LVP associated with CCM ($3.4 \pm 0.9$ vs. $2.9 \pm 0.9$ mm Hg, $P = \text{NS}$).
role of the stimulus but unrelated to the timing of the signal within the action potential plateau. This suggests that, while the timing of the CCM signal must occur within the absolute refractory period to avoid triggering an additional ventricular contraction, there is a stable window of opportunity in which CCM signals can be applied. The previously reported linear dependence between contractile enhancement and signal delay in isolated rabbit papillary muscles [4] is at odds with the current study. This may reflect differences in the experimental preparation utilised (i.e. isolated muscle strip vs. whole organ responses) and/or highlight the multifactorial mechanisms of CCM induced inotropic enhancement.

4.2. Intracardiac noradrenaline release and CCM

We have shown that the acute effects of CCM are abolished in the presence of the β1-adrenoceptor antagonist metoprolol and that CCM is associated with an increase in noradrenaline in samples of coronary effluent in a manner correlated with the magnitude of inotropic enhancement. It is therefore clear that noradrenaline release and concurrent activation of β1-adrenoceptors underlies the increase in LV inotropy and alterations in electrophysiology acutely associated with CCM in the rabbit heart. Our data are supported by the findings of Meyer et al. who found that the inotropic enhancement associated with refractory stimulation of the coronary sinus in sheep was completely abolished during β-adrenoceptor blockade [5]. Mohri et al. also reported a modest, but incomplete, inhibition of the inotropic response to CCM during perfusion with propranolol [3]. In contrast, the acute inotropic effects of CCM were preserved in the presence of propranolol in experiments performed in left and right isolated ventricular rabbit papillary muscles [4]. Previous investigators have reported that CCM is associated with an increase in the amplitude of the Ca2+ transient [3], phosphorylation of phospholamban [11] and that the inotropic response is dependent upon the entry of Ca2+ through the L-type Ca2+ channels [4]. These findings correlate with the well-described intracellular mechanisms whereby β1-adrenoceptor stimulation results in myocardium inotropic enhancement [13].

Whilst our study does not provide any specific details of intracellular calcium homeostasis during CCM inotropy, it is likely that adrenergic activation will stimulate the L-type calcium channel, promote calcium release from the sarcoplasmic reticulum and stimulate an increase in calcium reuptake into the sarcoplasmic reticulum via SERCA (secondary to phospholamban phosphorylation), although the lack of enhancement of the rate of pressure relaxation in the current study may refute this point.

The ventricular myocardium is richly innervated with efferent sympathetic nerve fibres and it is likely that these fibres are stimulated to release noradrenaline by the delivery of electrical signals to the epicardial surface. Importantly, several studies have previously shown that electrical signals, not specifically timed to the absolute refractory period, can be used to stimulate catecholamine release from the perfused whole hearts and from isolated samples of cardiac tissue [14,15]. The distribution of sympathetic nerve fibres throughout the ventricle has been shown to be heterogenous with a gradient of fibre density from basal (highest) to apical (lowest) regions [16,17]. We have previously shown that the expression of tyrosine hydroxylase protein,
an enzyme expressed in sympathetic nerve terminals, is greater in homogenates of rabbit ventricular tissue taken from basal than in those taken from apical regions [18]. Other studies have demonstrated a graded distribution of ventricular catecholamine content from the base to the apex in the canine heart [19] and reported greater proportion of adrenergic fibres innervating basal regions of the human and canine ventricular tissue [16,17]. These anatomical/histological findings provide a possible explanation for the differential inotropic effects noted during basal, midlevel and apical stimulation. In addition these data provide a greater understanding of the previously discussed relationships between signal amplitude (spatial), signal duration (temporal) and ventricular inotropy. The degree of inotropy likely reflects the proportion of sympathetic fibres stimulated within a given region or over a given period of time. Increases in signal amplitude will result in a greater spread of the electrical field and an increase in the current density (i.e. field intensity). As the spread and intensity of the electrical field is increased then a greater proportion of nerve fibres are likely to be stimulated resulting in a greater release of noradrenaline. This is reflected in our finding of a greater concentration of noradrenaline in samples of coronary effluent collected during CCM at high amplitudes. A further point for consideration is that stimulation within a given region may propagate the stimulation of nerves and release of noradrenaline throughout the ventricle. It is known that the myocardium exhibits a rich intrinsic innervation and that sympathetic efferent fibres run from basal to apical regions and innervate both epicardial and endocardial portions of the myocardium [20]. It seems unlikely that alterations in the signal delay should influence the contractile responses to CCM if such changes are mediated by catecholamine release from the sympathetic innervations of the LV, as our data indicate. Instead, varying CCM signal delivery is likely to be of critical clinical importance to avoid arrhythmias induced by inappropriately timed stimuli.

In the present study, CCM induced an increase in ventricular pressure development and contractility without significantly altering ventricular relaxation. These data are supported by the findings of Mohri et al. in the dog who reported no enhancement of either global or regional ventricular relaxation during CCM delivery to the ventricular epicardial surface [2]. In contrast, Meyer et al. found enhanced rates of ventricular relaxation during electrical stimulation in sheep [5]. It seems probable that this reflects the proportion of the myocardium, or more probably the proportion of sympathetic fibres, stimulated during CCM. Previous histological studies have identified a significant proportion of sympathetic fibres which cross the coronary sinus [20]. Therefore

---

**Fig. 8.** Role of the slow delayed rectifying potassium current in CCM induced shortening of ventricular mono-phasic action potential duration. Raw data illustrating the effect of CCM (Panel A) and isoprenaline (ISO, 5 nM) (Panel B) on monophasic action potential duration (MAPD) recorded from basal regions (BL = baseline). Mean data showing the effect of HMR 1556 (500 nM) on the shortening of MAPD induced by CCM (Panel C) and ISO (Panel D). The mean effects of HMR 1556 on the change in peak LVP induced by CCM (Panel E) and ISO (Panel F) (n = 6 CCM, 3 ISO).
electrical stimulation in this region may result in a large and more homogeneously distributed release of noradrenaline within the ventricle. The proportion of sympathetic fibres stimulated in the present study, and in that of Mohri et al.[2], may be insufficient to significantly alter global ventricular relaxation. In a recently published study Zhang et al. reported on the effects of CCM on cardiac function in rabbits with coronary ligation induced heart failure [21]. Acute CCM enhanced ventricular inotropy during stimulation at the anterior LV free wall and to a lesser degree during stimulation at the right ventricular septum. Ventricular instutropy was only enhanced during LV free wall stimulation. While no specific information is presented on the site and size of region stimulated in this study these data do provide evidence that the location of signal delivery is an important determinant of the effects of CCM on ventricular function. The findings of the present study do not rule out alterations in regional relaxation which are not reflected in global measures.

4.3. CCM and ventricular electrophysiology

We have shown that the duration of MAPs recorded proximal to the site of stimulation are significantly shortened in a manner dependent upon the amplitude, duration and location of the stimulus. To the best of our knowledge this is the first report of the electrophysiological effects directly recorded from sites close to the CCM signal in the whole heart and represents a finding of potential clinical importance (see later). In keeping with our theory of the adrenergic dependence of CCM, we found that the shortening of MAPD was abolished during perfusion with metoprolol. Conventionally accepted evidence in isolated myocytes [6] and the whole heart [22] indicate that activation of the β1-adrenoceptors promotes shortening of ventricular action potential duration. From a mechanistic standpoint we have demonstrated that the shortening of locally recorded MAPD is partially dependent on the activation of Iks. Iks forms the slow component of the delayed rectifier outward potassium current is responsible for the increased rate of repolarisation associated with adrenergic activation and is present in a number of animal species including the rabbit [6–10]. While Iks is reported to have little effect in un-stimulated conditions, it is activated by β-adrenoceptor stimulation and promotes a shortening of ventricular action potential duration (a result of protein kinase A dependent phosphorylation) [6]. The incomplete inhibition of CCM induced MAPD shortening by HMR 1556 suggests that other repolarising currents may be activated during CCM. β-adrenoceptor stimulation is known to increase the flow of ion currents through the L-type Ca2+ channels (Ica), Na+/Ca2+ exchanger (Ica,Na), Iks and chloride channels (IK,CL and IK,CAMP). Activation of IK will increase the outward current of negatively charged ions and could contribute to the shortening of ventricular APD during CCM. In addition the activation of Ca2+ uptake by the sarcoplasmic reticulum ATPase (SERCA) and the enhancement of Ca2+ release by the ryanodine receptors should produce a Ca2+ transient of greater amplitude but of reduced duration, though our functional evidence and the previous reports, using aequorin Ca2+ fluorescence in the ferret heart, suggest that the Ca2+ duration is unaffected by CCM. We also cannot rule out the actions of other co-released neurotransmitters from adrenergic stimulation other than noradrenaline.

Previous investigators have suggested that CCM can induce enhanced calcium entry into the myocytes through direct modification of the L-type calcium channels. These early studies in isolated rabbit papillary muscles suggest that an enhancement of calcium influx prolongs APD [4]. In contrast, we have found that CCM induces shortening of ventricular MAPD in a manner dependent upon β1-adrenoceptor stimulation, likely occurring secondary to catecholamine release from sympathetic nerve fibres. While it cannot be ruled out that these differences reflect the species of animal, the type of preparation and/or the methods utilised in each study, our data provide the first evidence of the electrophysiological effects of CCM in the whole heart. The inotropic and electrophysiological effects of β1-adrenoceptor stimulation (see above) are well described and can account for a number of the molecular changes noted in previous studies with CCM (i.e. increased L-type calcium current and phosphorylation of phospholamban).

4.4. Clinical implications

Our study indicates that β1-adrenoceptor activation is primarily responsible for the acute inotropic enhancement and electrophysiological changes associated with CCM. This has obvious clinical implications since current treatment guidelines indicate the use of β1-adrenoceptor antagonists in the treatment of patients with systolic heart failure. Interestingly, experimental studies in dogs with microembolism induced heart failure have shown additive beneficial effects when CCM therapy was combined with β1-adrenoceptor antagonism [11]. Moreover, the results of clinical studies conducted to date show that CCM therapy used in conjunction with traditional pharmacological therapies increases patient exercise capacity improves quality of life measures and is able to reverse the detrimental molecular and structural remodelling associated with heart failure [23–25]. It is unlikely that complete inhibition of the β1-adrenoceptors is achieved in the clinical situation, owing to the adverse side-effects of the high doses of β1-adrenoceptor blocking drugs that would be required, and so CCM may still be effective in these patients. It is known that acute inotropic effects of CCM were still observed in early feasibility studies conducted in patients with systolic heart failure who were receiving optimised medical therapy (including β1-adrenoceptor antagonists) [26]. The intermittent nature of CCM therapy, which utilises periods with and without CCM stimulation, may be akin to exercise therapy which has been shown to have beneficial effects in patients with varying degrees of heart failure and who are already receiving β-blockade therapy [12]. It also cannot be ruled out that the long-term benefit of CCM therapy are mediated by other mechanisms than those which mediate the acute inotropic effects, this could include the release of other autonomic factors.

Previous attempts to utilise inotropic pharmacological agents in the treatment of heart failure have been unsuccessful; resulting in a greater number of patient deaths in the treatment arm of these studies [27]. However results from large scale clinical trials with CCM therapy (i.e. FIX-HF4 [23] and the preliminary findings of FIX-HFS [24] suggest that CCM does not alter patient mortality rates at 3–6 months follow up. It is tempting to hypothesise that the localised stimulation of catecholamine release avoids the systemic complications and chronic effects of pharmacological agents, though greater patient numbers and longer follow-up data are required.

The local specific electrophysiological effects of CCM raises the question of whether CCM is pro-arrhythmic as regional variations in repolarisation could promote the development of re-entrant arrhythmias. In addition, we have previously shown that sympathetic activation increases the susceptibility to ventricular fibrillation in experimental conditions [28] and there is clear link between sympathetic drive and an increase in arrhythmic risk in clinical studies [29,30]. Therefore it seems plausible that CCM has a potential to increase the risk of ventricular arrhythmias, although preliminary anecdotal evidence does not support this suggestion. Clinical studies conducted to date suggest that CCM is not associated with any increase in hospitalisations for arrhythmic events [23,24], though more robust and rigorous scientific evidence is needed to support these short term epidemiological findings.

5. Conclusions

We have demonstrated that the acute inotropic and electrophysiological effects of CCM therapy are associated with the release of noradrenaline and concurrent stimulation of β1-adrenoceptors. In
contrast to early reports we found that CCM was associated with a shortening of ventricular MAPD in a manner partially dependent upon the activation of \(I_{ks}\), a finding which may be of clinical importance.

### 6. Disclosures

The funding bodies played no role in the study design; collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit this work for publication.

### Acknowledgements

This work is supported by funds from a British Heart Foundation Project Grant. The study is part of the research portfolio supported by the Leicester NIHR Biomedical Research Unit in Cardiovascular Disease. HMR 1556 was the kind gift of Dr. Jürgen Pünter (Aventis Pharma Deutschland GmbH).

### References


